Dermatan sulfate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Dermatan sulfate is a medication indicated to prevent deep vein thrombosis.

Generic Name
Dermatan sulfate
DrugBank Accession Number
DB15880
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 475.38
Monoisotopic: 475.064287314
Chemical Formula
C14H21NO15S
Synonyms
  • beta-Heparin
  • Chondroitin sulfate B
  • Chondroitinsulfuric acid type B
  • Dermatan 4-sulfate
  • Dermatan hydrogen sulfate
  • Dermatan L-iduronate
  • Dermatan sulfate, low molecular weight
  • Dermatan sulphate
External IDs
  • MF 701
  • MF-701

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prevention ofDeep vein thrombosis••••••••••••••••••••••••••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Dermatan sulfate.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Dermatan sulfate.
AcemetacinThe risk or severity of bleeding and hemorrhage can be increased when Dermatan sulfate is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Dermatan sulfate.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Dermatan sulfate.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Dermatan sulfate sodiumNot AvailableNot AvailableNot applicable

Categories

ATC Codes
B01AX04 — Dermatan sulfate
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
J3OC7JVS54
CAS number
24967-94-0
InChI Key
AVJBPWGFOQAPRH-FWMKGIEWSA-L
InChI
InChI=1S/C14H23NO15S/c1-3(17)15-5-10(9(30-31(24,25)26)4(2-16)27-13(5)23)28-14-8(20)6(18)7(19)11(29-14)12(21)22/h4-11,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)/p-2/t4-,5-,6+,7+,8-,9+,10-,11-,13-,14-/m1/s1
IUPAC Name
(2R,3S,4S,5R,6R)-6-{[(2R,3R,4R,5R,6R)-3-acetamido-2-hydroxy-6-(hydroxymethyl)-5-(sulfonatooxy)oxan-4-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylate
SMILES
CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@@H]1O[C@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O

References

General References
  1. AIFA Product Information: MISTRAL (dermatan sulfate) injection [Link]
ChemSpider
30361
Wikipedia
Dermatan_sulfate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular100 MG/2ML
Injection, solutionIntramuscular200 MG/2ML
Injection, solutionIntramuscular300 MG/3ML
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-6.4Chemaxon
pKa (Strongest Acidic)-1.9Chemaxon
pKa (Strongest Basic)-3.7Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count14Chemaxon
Hydrogen Donor Count6Chemaxon
Polar Surface Area264.5 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity99.01 m3·mol-1Chemaxon
Polarizability40.06 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-209.1875258
predicted
DarkChem Lite v0.1.0
[M-H]-187.47469
predicted
DeepCCS 1.0 (2019)
[M+H]+209.4681258
predicted
DarkChem Lite v0.1.0
[M+H]+189.2996
predicted
DeepCCS 1.0 (2019)
[M+Na]+209.4400258
predicted
DarkChem Lite v0.1.0
[M+Na]+194.90538
predicted
DeepCCS 1.0 (2019)

Drug created at September 24, 2020 17:17 / Updated at December 01, 2022 11:30